{"id":227804,"date":"2025-12-25T06:06:31","date_gmt":"2025-12-25T12:06:31","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/framework-can-improve-alzheimers-treatment-efficacy-by-tracking-anti-a%ce%b2-therapy-response"},"modified":"2025-12-25T06:06:31","modified_gmt":"2025-12-25T12:06:31","slug":"framework-can-improve-alzheimers-treatment-efficacy-by-tracking-anti-a%ce%b2-therapy-response","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/framework-can-improve-alzheimers-treatment-efficacy-by-tracking-anti-a%ce%b2-therapy-response","title":{"rendered":"Framework can improve Alzheimer\u2019s treatment efficacy by tracking anti-A\u03b2 therapy response"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/framework-can-improve-alzheimers-treatment-efficacy-by-tracking-anti-aceb2-therapy-response.jpg\"><\/a><\/p>\n<p>In the last few years, progress has been made in the fight against Alzheimer\u2019s disease with a class of therapies called anti-amyloid antibodies (anti-A\u03b2). These monoclonal anti-A\u03b2s are proteins made in a laboratory to stimulate the immune system to slow the progression of the disease by targeting amyloid plaques in the brain that are characteristic of Alzheimer\u2019s.<\/p>\n<p>Biomarkers, such as measures derived from PET scans that reflect amyloid plaques in the brain, were instrumental in FDA approval of anti-A\u03b2 therapies, like lecanumab (Leqembi) and donanemab (Kisulna), and have been shown to reduce plaques in the brains of Alzheimer\u2019s patients. Yet despite FDA approval, there is still a clinical need to better understand how to monitor the efficacy and safety of these treatments.<\/p>\n<p>To this end, the Alzheimer\u2019s Association convened a workgroup of scientists and clinicians with experience in Alzheimer\u2019s disease, including clinical trials of anti-A\u03b2 therapies and biomarkers, to propose a framework to characterize the response of patients receiving these treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the last few years, progress has been made in the fight against Alzheimer\u2019s disease with a class of therapies called anti-amyloid antibodies (anti-A\u03b2). These monoclonal anti-A\u03b2s are proteins made in a laboratory to stimulate the immune system to slow the progression of the disease by targeting amyloid plaques in the brain that are characteristic [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-227804","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=227804"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227804\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=227804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=227804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=227804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}